Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-LARC2 Vaccine for Malaria Prevention in Burkina Faso
NCT07385287Phase 2Recruiting
- Sponsor
- Sanaria Inc.
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PfSPZ-LARC2 in malaria, sponsored by Sanaria Inc.. Started May 2026; status: recruiting.
02
Drugs
PfSPZ-LARC2
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07385287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385287.